Tag: closing

FORM 8.3

FORM 8.5 (EPT/RI)

MELBOURNE, Australia, July 24, 2025 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.

Irvine, CA, July 24, 2025 (GLOBE NEWSWIRE) -- Linkhome Holdings Inc. (“Linkhome” or the “Company”) (Nasdaq: LHAI), a leading AI-powered real estate platform leveraging artificial intelligence and fintech to make homeownership simpler, faster, and more accessible for all Americans, today announced the pricing of its upsized initial public offering (the “Offering”). The Offering consists of 1,500,000 shares of common stock priced at a public offering price of $4 per share, for total gross proceeds of $6,000,000, before deducting underwriting discounts and offering expenses. The shares of common stock have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on Jul 24, 2025, under the ticker symbol “LHAI.”

Miami, FL, July 23, 2025 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital energy and infrastructure company, today announced the pricing of its upsized offering of $950 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”). The notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). MARA also granted to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $200 million aggregate principal amount of the notes. The offering is expected to close on July 25, 2025, subject to satisfaction of customary closing conditions.

Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share.

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW